

# Building better monoclonal antibody-based therapeutic

Nature Reviews Cancer

15, 361-370

DOI: [10.1038/nrc3930](https://doi.org/10.1038/nrc3930)

Citation Report

| #  | ARTICLE                                                                                                                                                                                                                                | IF  | CITATIONS |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 1  | Research and development of therapeutic mAbs: An analysis based on pipeline projects. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 2769-2776.                                                                              | 1.4 | 34        |
| 2  | Cancer immunotherapy: Strategies for personalization and combinatorial approaches. <i>Molecular Oncology</i> , 2015, 9, 2043-2053.                                                                                                     | 2.1 | 87        |
| 3  | Pepsin-Containing Membranes for Controlled Monoclonal Antibody Digestion Prior to Mass Spectrometry Analysis. <i>Analytical Chemistry</i> , 2015, 87, 10942-10949.                                                                     | 3.2 | 29        |
| 4  | Viscosity-Lowering Effect of Amino Acids and Salts on Highly Concentrated Solutions of Two IgG1 Monoclonal Antibodies. <i>Molecular Pharmaceutics</i> , 2015, 12, 4478-4487.                                                           | 2.3 | 75        |
| 5  | QbD Implementation in Biotechnological Product Development Studies. , 0, , .                                                                                                                                                           |     | 4         |
| 6  | Trends in Biotechnological Drugs for Cancer Treatment. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2016, 11, 112-120.                                                                                                        | 0.8 | 2         |
| 7  | Fusion of Zif268 to the C-Terminus of Scfv Promotes Expression of the Active Form in the Cytoplasm of <i>Escherichia coli</i> . <i>Biochemistry &amp; Molecular Biology Journal</i> , 2016, 02, .                                      | 0.3 | 5         |
| 8  | Effect of Thermal and Shear Stressors on the Physical Properties, Structural Integrity and Biological Activity of the Anti-TNF-alpha Monoclonal Antibody, Infliximab. <i>Current Pharmaceutical Biotechnology</i> , 2016, 17, 905-914. | 0.9 | 12        |
| 9  | Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and Proteins. <i>Frontiers in Immunology</i> , 2016, 7, 394.                                                                  | 2.2 | 72        |
| 10 | Dysregulated Expression of Glycolipids in Tumor Cells: From Negative Modulator of Anti-tumor Immunity to Promising Targets for Developing Therapeutic Agents. <i>Frontiers in Oncology</i> , 2015, 5, 300.                             | 1.3 | 32        |
| 11 | Targeted Radionuclide Therapy of Human Tumors. <i>International Journal of Molecular Sciences</i> , 2016, 17, 33.                                                                                                                      | 1.8 | 130       |
| 13 | Novel Antibody Therapeutics Targeting Mesothelin In Solid Tumors. <i>Clinical Cancer Drugs</i> , 2016, 3, 76-86.                                                                                                                       | 0.3 | 45        |
| 14 | Circulating Tumor Cells and Circulating Tumor DNA Provide New Insights into Pancreatic Cancer. <i>International Journal of Medical Sciences</i> , 2016, 13, 902-913.                                                                   | 1.1 | 16        |
| 15 | Targeting plasma cells: are we any closer to a panacea for diseases of antibody-secreting cells?. <i>Immunological Reviews</i> , 2016, 270, 78-94.                                                                                     | 2.8 | 10        |
| 17 | OUP accepted manuscript. <i>Protein Engineering, Design and Selection</i> , 2016, 30, 15-21.                                                                                                                                           | 1.0 | 7         |
| 18 | Physicochemical characterization of biopharmaceuticals. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 130, 366-389.                                                                                                 | 1.4 | 58        |
| 19 | Emerging antibodies for the treatment of multiple myeloma. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 225-237.                                                                                                                | 1.0 | 25        |
| 20 | The Interplay of Antigen Affinity, Internalization, and Pharmacokinetics on CD44-Positive Tumor Targeting of Monoclonal Antibodies. <i>Molecular Pharmaceutics</i> , 2016, 13, 1894-1903.                                              | 2.3 | 20        |

| #  | ARTICLE                                                                                                                                                                                                                 | IF   | CITATIONS |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 21 | Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions. <i>Journal of Immunology</i> , 2016, 197, 1762-1775.                  | 0.4  | 50        |
| 22 | One-pot N-glycosylation remodeling of IgG with non-natural sialylglycopeptides enables glycosite-specific and dual-payload antibody-drug conjugates. <i>Organic and Biomolecular Chemistry</i> , 2016, 14, 9501-9518.   | 1.5  | 88        |
| 23 | Discovery of functional monoclonal antibodies targeting G-protein-coupled receptors and ion channels. <i>Biochemical Society Transactions</i> , 2016, 44, 831-837.                                                      | 1.6  | 14        |
| 24 | Theranostic Nanocages for Imaging and Photothermal Therapy of Prostate Cancer Cells by Active Targeting of Neuropeptide-Y Receptor. <i>Bioconjugate Chemistry</i> , 2016, 27, 2911-2922.                                | 1.8  | 24        |
| 26 | Bispecific antibodies in cancer immunotherapy. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 2491-2500.                                                                                                      | 1.4  | 40        |
| 27 | Kinetic exclusion assay of monoclonal antibody affinity to the membrane protein Roundabout 1 displayed on baculovirus. <i>Analytical Biochemistry</i> , 2016, 504, 41-49.                                               | 1.1  | 11        |
| 28 | Polymeric nanostructured materials for biomedical applications. <i>Progress in Polymer Science</i> , 2016, 60, 86-128.                                                                                                  | 11.8 | 257       |
| 29 | Antigen-specific immunotherapy for acute myeloid leukemia: where are we now, and where do we go from here?. <i>Expert Review of Hematology</i> , 2016, 9, 335-350.                                                      | 1.0  | 20        |
| 30 | Targeted therapy in cancer. <i>Medicine</i> , 2016, 44, 34-38.                                                                                                                                                          | 0.2  | 23        |
| 31 | Cytotoxic mechanisms of immunotherapy: Harnessing complement in the action of anti-tumor monoclonal antibodies. <i>Seminars in Immunology</i> , 2016, 28, 309-316.                                                      | 2.7  | 62        |
| 32 | Promises and pitfalls for recombinant oligoclonal antibodies-based therapeutics in cancer and infectious disease. <i>Current Opinion in Immunology</i> , 2016, 40, 51-61.                                               | 2.4  | 12        |
| 33 | Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 655-674. | 1.4  | 21        |
| 34 | Leukaemia 'firsts' in cancer research and treatment. <i>Nature Reviews Cancer</i> , 2016, 16, 163-172.                                                                                                                  | 12.8 | 67        |
| 35 | Safety of monoclonal antibodies and related therapeutic proteins for the treatment of neovascular macular degeneration: addressing outstanding issues. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 75-87.          | 1.0  | 8         |
| 36 | Development of therapeutic antibodies to G protein-coupled receptors and ion channels: Opportunities, challenges and their therapeutic potential in respiratory diseases. , 2017, 169, 113-123.                         |      | 18        |
| 37 | Application of Tryptophan Fluorescence Bandwidth-Maximum Plot in Analysis of Monoclonal Antibody Structure. <i>AAPS PharmSciTech</i> , 2017, 18, 838-845.                                                               | 1.5  | 8         |
| 38 | Effector-attenuating Substitutions That Maintain Antibody Stability and Reduce Toxicity in Mice. <i>Journal of Biological Chemistry</i> , 2017, 292, 3900-3908.                                                         | 1.6  | 206       |
| 39 | Use of polyclonal/monoclonal antibody therapies in transplantation. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 339-352.                                                                                    | 1.4  | 9         |

| #  | ARTICLE                                                                                                                                                                                                                                                  | IF  | CITATIONS |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 40 | Anti-Folate Receptor- $\hat{\pm}$ IgE but not IgG Recruits Macrophages to Attack Tumors via TNF $\hat{\pm}$ /MCP-1 Signaling. <i>Cancer Research</i> , 2017, 77, 1127-1141.                                                                              | 0.4 | 58        |
| 41 | Tocilizumab $\hat{\pm}$ Alendronate Conjugate for Treatment of Rheumatoid Arthritis. <i>Bioconjugate Chemistry</i> , 2017, 28, 1084-1092.                                                                                                                | 1.8 | 25        |
| 42 | What potential do aptamers hold in therapeutic delivery?. <i>Therapeutic Delivery</i> , 2017, 8, 53-55.                                                                                                                                                  | 1.2 | 4         |
| 43 | Antibodies: From novel repertoires to defining and refining the structure of biologically important targets. <i>Methods</i> , 2017, 116, 12-22.                                                                                                          | 1.9 | 6         |
| 44 | Dynamics of a tumor-immune model considering targeted chemotherapy. <i>Chaos, Solitons and Fractals</i> , 2017, 98, 7-13.                                                                                                                                | 2.5 | 20        |
| 45 | Biological Therapies of Immunologic Diseases. <i>Immunology and Allergy Clinics of North America</i> , 2017, 37, 247-259.                                                                                                                                | 0.7 | 5         |
| 46 | Improved Targeting of Cancers with Nanotherapeutics. <i>Methods in Molecular Biology</i> , 2017, 1530, 13-37.                                                                                                                                            | 0.4 | 11        |
| 47 | Immunoprotein-Mediated siRNA Delivery. <i>Molecular Pharmaceutics</i> , 2017, 14, 1339-1351.                                                                                                                                                             | 2.3 | 21        |
| 48 | Heat-shock protein 27 (HSP27, HSPB1) is synthetic lethal to cells with oncogenic activation of MET, EGFR and BRAF. <i>Molecular Oncology</i> , 2017, 11, 599-611.                                                                                        | 2.1 | 32        |
| 49 | Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase C. <i>Investigational New Drugs</i> , 2017, 35, 235-241. | 1.2 | 16        |
| 50 | Eradication of Tumors through Simultaneous Ablation of CD276/B7-H3-Positive Tumor Cells and Tumor Vasculature. <i>Cancer Cell</i> , 2017, 31, 501-515.e8.                                                                                                | 7.7 | 280       |
| 51 | Recombinant Immunotoxins for Chronic Inflammatory Disease. <i>Milestones in Drug Therapy</i> , 2017, , 131-150.                                                                                                                                          | 0.1 | 0         |
| 52 | Childhood Acute Lymphoblastic Leukemia. , 2017, , .                                                                                                                                                                                                      |     | 2         |
| 53 | Biophysical study of bevacizumab structure and bioactivity under thermal and pH-stresses. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 105, 127-136.                                                                                       | 1.9 | 23        |
| 54 | Affinity of human IgG subclasses to mouse Fc gamma receptors. <i>MAbs</i> , 2017, 9, 767-773.                                                                                                                                                            | 2.6 | 175       |
| 55 | Immunoglobulin domain interface exchange as a platform technology for the generation of Fc heterodimers and bispecific antibodies. <i>Journal of Biological Chemistry</i> , 2017, 292, 9745-9759.                                                        | 1.6 | 35        |
| 56 | Therapeutic IgE Antibodies: Harnessing a Macrophage-Mediated Immune Surveillance Mechanism against Cancer. <i>Cancer Research</i> , 2017, 77, 2779-2783.                                                                                                 | 0.4 | 42        |
| 57 | Delivering safer immunotherapies for cancer. <i>Advanced Drug Delivery Reviews</i> , 2017, 114, 79-101.                                                                                                                                                  | 6.6 | 233       |

| #  | ARTICLE                                                                                                                                                                                                                      | IF  | CITATIONS |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 58 | Combinatorial drug delivery approaches for immunomodulation. <i>Advanced Drug Delivery Reviews</i> , 2017, 114, 161-174.                                                                                                     | 6.6 | 42        |
| 59 | A new paradigm for antiangiogenic therapy through controlled release of bevacizumab from PLGA nanoparticles. <i>Scientific Reports</i> , 2017, 7, 3736.                                                                      | 1.6 | 92        |
| 60 | Ocular delivery systems for the administration of antibody therapeutics. <i>Journal of Pharmaceutical Investigation</i> , 2017, 47, 373-382.                                                                                 | 2.7 | 5         |
| 61 | IgG Fc domains that bind C1q but not effector Fc $\gamma$ 3 receptors delineate the importance of complement-mediated effector functions. <i>Nature Immunology</i> , 2017, 18, 889-898.                                      | 7.0 | 122       |
| 62 | Surrogate CD16-expressing effector cell lines for determining the bioactivity of therapeutic monoclonal antibodies. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 143, 188-198.                           | 1.4 | 6         |
| 63 | New platform for simple and rapid protein-based affinity reactions. <i>Scientific Reports</i> , 2017, 7, 178.                                                                                                                | 1.6 | 18        |
| 64 | Thiol-Reactive Star Polymers Display Enhanced Association with Distinct Human Blood Components. <i>ACS Applied Materials &amp; Interfaces</i> , 2017, 9, 12182-12194.                                                        | 4.0 | 24        |
| 65 | From rabbit antibody repertoires to rabbit monoclonal antibodies. <i>Experimental and Molecular Medicine</i> , 2017, 49, e305-e305.                                                                                          | 3.2 | 118       |
| 66 | Next Generation Antibody Drug Conjugates (ADCs) and Immunotoxins. <i>Milestones in Drug Therapy</i> , 2017, , .                                                                                                              | 0.1 | 3         |
| 67 | Emerging trends and new developments in monoclonal antibodies: A scientometric analysis (1980-2016). <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 1388-1397.                                                     | 1.4 | 21        |
| 68 | Severe Oral Ulcers Associated With Nivolumab Treatment. <i>JAMA Dermatology</i> , 2017, 153, 235.                                                                                                                            | 2.0 | 11        |
| 69 | Three-Dimensional Ordered Antibody Arrays Through Self-Assembly of Antibody-Polymer Conjugates. <i>Angewandte Chemie</i> , 2017, 129, 1293-1297.                                                                             | 1.6 | 1         |
| 70 | Three-Dimensional Ordered Antibody Arrays Through Self-Assembly of Antibody-Polymer Conjugates. <i>Angewandte Chemie - International Edition</i> , 2017, 56, 1273-1277.                                                      | 7.2 | 31        |
| 71 | Rapid Distinction of Leucine and Isoleucine in Monoclonal Antibodies Using Nanoflow LCMS. <i>Analytical Chemistry</i> , 2017, 89, 720-727.                                                                                   | 3.2 | 17        |
| 72 | Antibody-siRNA conjugates: drugging the undruggable for anti-leukemic therapy. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 325-338.                                                                              | 1.4 | 28        |
| 73 | Blocking the CCL2-CCR2 Axis Using CCL2-Neutralizing Antibody Is an Effective Therapy for Hepatocellular Cancer in a Mouse Model. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 312-322.                                   | 1.9 | 101       |
| 74 | Role of Fc-Fc $\gamma$ 3R interactions in the antitumor activity of therapeutic antibodies. <i>Immunology and Cell Biology</i> , 2017, 95, 340-346.                                                                          | 1.0 | 35        |
| 75 | An Fc Double-Engineered CD20 Antibody with Enhanced Ability to Trigger Complement-Dependent Cytotoxicity and Antibody-Dependent Cell-Mediated Cytotoxicity. <i>Transfusion Medicine and Hemotherapy</i> , 2017, 44, 292-300. | 0.7 | 28        |

| #  | ARTICLE                                                                                                                                                                                                                                                                                         | IF  | CITATIONS |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 76 | Sequence composition predicts immunoglobulin superfamily members that could share the intrinsically disordered properties of antibody CH1 domains. <i>Scientific Reports</i> , 2017, 7, 12404.                                                                                                  | 1.6 | 7         |
| 77 | Targeted killing of prostate cancer cells using antibody-drug conjugated carbon nanohorns. <i>Journal of Materials Chemistry B</i> , 2017, 5, 8821-8832.                                                                                                                                        | 2.9 | 20        |
| 78 | Characterization of 30 therapeutic antibodies and related products by size exclusion chromatography: Feasibility assessment for future mass spectrometry hyphenation. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2017, 1065-1066, 35-43. | 1.2 | 73        |
| 79 | Bridging Bio-Nano Science and Cancer Nanomedicine. <i>ACS Nano</i> , 2017, 11, 9594-9613.                                                                                                                                                                                                       | 7.3 | 304       |
| 80 | Identification and verification of hybridoma-derived monoclonal antibody variable region sequences using recombinant DNA technology and mass spectrometry. <i>Molecular Immunology</i> , 2017, 90, 287-294.                                                                                     | 1.0 | 13        |
| 81 | Antisense oligonucleotide and thyroid hormone conjugates for obesity treatment. <i>Scientific Reports</i> , 2017, 7, 9307.                                                                                                                                                                      | 1.6 | 11        |
| 82 | Identification of senescent cell surface targetable protein DPP4. <i>Genes and Development</i> , 2017, 31, 1529-1534.                                                                                                                                                                           | 2.7 | 168       |
| 83 | Untangling Fc and complement receptors to kill tumors. <i>Nature Immunology</i> , 2017, 18, 874-875.                                                                                                                                                                                            | 7.0 | 3         |
| 84 | Cell-surface cascaded landing location for nanotheranostics. <i>Chinese Chemical Letters</i> , 2017, 28, 1799-1800.                                                                                                                                                                             | 4.8 | 13        |
| 86 | Elucidating the weak protein-protein interaction mechanisms behind the liquid-liquid phase separation of a mAb solution by different types of additives. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2017, 120, 1-8.                                                        | 2.0 | 22        |
| 87 | Novel prostate cancer immunotherapy with a DNA-encoded anti-prostate-specific membrane antigen monoclonal antibody. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1577-1588.                                                                                                              | 2.0 | 31        |
| 88 | Antibody Tumor Targeting Is Enhanced by CD27 Agonists through Myeloid Recruitment. <i>Cancer Cell</i> , 2017, 32, 777-791.e6.                                                                                                                                                                   | 7.7 | 52        |
| 89 | Antibody-Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments. <i>Targeted Oncology</i> , 2017, 12, 719-739.                                                                                                                                          | 1.7 | 71        |
| 90 | Ovarian Cancers. , 2017, , .                                                                                                                                                                                                                                                                    |     | 1         |
| 91 | Dual targeting of <sc>EGFR</sc> and <sc>ERBB2</sc> pathways produces a synergistic effect on cancer cell proliferation and migration <i>in vitro</i> . <i>Veterinary and Comparative Oncology</i> , 2017, 15, 890-909.                                                                          | 0.8 | 11        |
| 92 | abYsis: Integrated Antibody Sequence and Structure Management, Analysis, and Prediction. <i>Journal of Molecular Biology</i> , 2017, 429, 356-364.                                                                                                                                              | 2.0 | 141       |
| 93 | Utilizing combinatorial engineering to develop Tie2 targeting antagonistic angiopoetin-2 ligands as candidates for anti-angiogenesis therapy. <i>Oncotarget</i> , 2017, 8, 33571-33585.                                                                                                         | 0.8 | 4         |
| 94 | A Strategy for Screening Monoclonal Antibodies for Arabidopsis Flowers. <i>Frontiers in Plant Science</i> , 2017, 8, 270.                                                                                                                                                                       | 1.7 | 3         |

| #   | ARTICLE                                                                                                                                                                                                                                                                                                                                    | IF  | CITATIONS |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 95  | Immunotherapy Clinical Trials in Neuro-Oncology. , 2017, , 181-210.                                                                                                                                                                                                                                                                        |     | 0         |
| 97  | Strategies for Selecting Membrane Protein-Specific Antibodies using Phage Display with Cell-Based Panning. <i>Antibodies</i> , 2017, 6, 10.                                                                                                                                                                                                | 1.2 | 32        |
| 98  | Genomic Variations in Pancreatic Cancer and Potential Opportunities for Development of New Approaches for Diagnosis and Treatment. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1201.                                                                                                                                    | 1.8 | 14        |
| 99  | Unique therapeutic properties and preparation methodology of multivalent rituximab-lipid nanoparticles. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2017, 117, 256-269.                                                                                                                                                | 2.0 | 4         |
| 100 | Decoding the Human Immunoglobulin G-Glycan Repertoire Reveals a Spectrum of Fc-Receptor- and Complement-Mediated-Effector Activities. <i>Frontiers in Immunology</i> , 2017, 8, 877.                                                                                                                                                       | 2.2 | 269       |
| 101 | Nanobodies As Novel Agents for Targeting Angiogenesis in Solid Cancers. <i>Frontiers in Immunology</i> , 2017, 8, 1746.                                                                                                                                                                                                                    | 2.2 | 45        |
| 102 | Single-Domain Antibodies As Therapeutics against Human Viral Diseases. <i>Frontiers in Immunology</i> , 2017, 8, 1802.                                                                                                                                                                                                                     | 2.2 | 78        |
| 103 | Identification of Novel Epitopes with Agonistic Activity for the Development of Tumor Immunotherapy Targeting TRAIL-R1. <i>Journal of Cancer</i> , 2017, 8, 2542-2553.                                                                                                                                                                     | 1.2 | 2         |
| 104 | Humoral response in experimental autoimmune encephalomyelitis targets neural precursor cells in the central nervous system of naive rodents. <i>Journal of Neuroinflammation</i> , 2017, 14, 227.                                                                                                                                          | 3.1 | 7         |
| 105 | HER2-specific recombinant immunotoxin 4D5scFv-PE40 passes through retrograde trafficking route and forces cells to enter apoptosis. <i>Oncotarget</i> , 2017, 8, 22048-22058.                                                                                                                                                              | 0.8 | 22        |
| 106 | Droplet-Digital PCR Provides a Rapid, Accurate and Cost-Effective Method for Identification of Biomarker FcγRIIIa-F158V Genotypes. <i>Gene Technology</i> , 2017, 06, .                                                                                                                                                                    | 0.5 | 4         |
| 107 | Single-Cell Droplet Microfluidic Screening for Antibodies Specifically Binding to Target Cells. <i>Cell Reports</i> , 2018, 22, 2206-2215.                                                                                                                                                                                                 | 2.9 | 149       |
| 108 | Carbohydrate-based vaccines for oncotherapy. <i>Medicinal Research Reviews</i> , 2018, 38, 1003-1026.                                                                                                                                                                                                                                      | 5.0 | 64        |
| 109 | Development of an analytical method to assess the occupational health risk of therapeutic monoclonal antibodies using LC-HRMS. <i>Analytical and Bioanalytical Chemistry</i> , 2018, 410, 2829-2836.                                                                                                                                       | 1.9 | 6         |
| 110 | Protein A affinity chromatography of Chinese hamster ovary (CHO) cell culture broths containing biopharmaceutical monoclonal antibody (mAb): Experiments and mechanistic transport, binding and equilibrium modeling. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2018, 1083, 44-56. | 1.2 | 20        |
| 111 | Tumor uptake of pegylated diabodies: Balancing systemic clearance and vascular transport. <i>Journal of Controlled Release</i> , 2018, 279, 126-135.                                                                                                                                                                                       | 4.8 | 17        |
| 112 | Immunostimulation and Immunosuppression: Nanotechnology on the Brink. <i>Small Methods</i> , 2018, 2, 1700347.                                                                                                                                                                                                                             | 4.6 | 32        |
| 113 | Efficacy and Mechanism of Antitumor Activity of an Antibody Targeting Transferrin Receptor 1 in Mouse Models of Human Multiple Myeloma. <i>Journal of Immunology</i> , 2018, 200, 3485-3494.                                                                                                                                               | 0.4 | 22        |

| #   | ARTICLE                                                                                                                                                                                                                | IF   | CITATIONS |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 114 | Polymeric microneedles for transdermal protein delivery. <i>Advanced Drug Delivery Reviews</i> , 2018, 127, 106-118.                                                                                                   | 6.6  | 242       |
| 115 | Highly homogeneous antibody modification through optimisation of the synthesis and conjugation of functionalised dibromopyridazinediones. <i>Organic and Biomolecular Chemistry</i> , 2018, 16, 1359-1366.             | 1.5  | 60        |
| 116 | Restricted processing of CD16a/Fc $\gamma$ 3 receptor IIIa N-glycans from primary human NK cells impacts structure and function. <i>Journal of Biological Chemistry</i> , 2018, 293, 3477-3489.                        | 1.6  | 63        |
| 117 | Synthesis of a novel HER2 targeted aza-BODIPY antibody conjugate: synthesis, photophysical characterisation and <i>in vitro</i> evaluation. <i>Organic and Biomolecular Chemistry</i> , 2018, 16, 1144-1149.           | 1.5  | 17        |
| 119 | Reprogramming immune proteins as therapeutics using molecular engineering. <i>Current Opinion in Chemical Engineering</i> , 2018, 19, 27-34.                                                                           | 3.8  | 9         |
| 120 | Immunoengineering with biomaterials for enhanced cancer immunotherapy. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2018, 10, e1506.                                                   | 3.3  | 33        |
| 121 | Using Chemical Synthesis To Study and Apply Protein Glycosylation. <i>Biochemistry</i> , 2018, 57, 413-428.                                                                                                            | 1.2  | 20        |
| 122 | Monoclonal antibody higher order structure analysis by high throughput protein conformational array. <i>MAbs</i> , 2018, 10, 397-405.                                                                                  | 2.6  | 11        |
| 123 | Trends involving monoclonal antibody (mAb) research and commercialization: A scientometric analysis of IMS Lifecycle R&D Focus Database (1980-2016). <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 847-855. | 1.4  | 9         |
| 124 | Intermolecular interactions in highly concentrated formulations of recombinant therapeutic proteins. <i>Current Opinion in Biotechnology</i> , 2018, 53, 59-64.                                                        | 3.3  | 24        |
| 125 | Neutrophil-Based Drug Delivery Systems. <i>Advanced Materials</i> , 2018, 30, e1706245.                                                                                                                                | 11.1 | 236       |
| 126 | Antibody Therapy. , 2018, , .                                                                                                                                                                                          |      | 0         |
| 127 | Tailoring Porous Silicon for Biomedical Applications: From Drug Delivery to Cancer Immunotherapy. <i>Advanced Materials</i> , 2018, 30, e1703740.                                                                      | 11.1 | 127       |
| 128 | Overcoming multiple myeloma drug resistance in the era of cancer omics™. <i>Leukemia and Lymphoma</i> , 2018, 59, 542-561.                                                                                             | 0.6  | 34        |
| 129 | In Vitro Modeling of Tumor-Immune System Interaction. <i>ACS Biomaterials Science and Engineering</i> , 2018, 4, 314-323.                                                                                              | 2.6  | 21        |
| 130 | Beyond binding: antibody effector functions in infectious diseases. <i>Nature Reviews Immunology</i> , 2018, 18, 46-61.                                                                                                | 10.6 | 516       |
| 131 | Intracellular response to process optimization and impact on productivity and product aggregates for a high-titer CHO cell process. <i>Biotechnology and Bioengineering</i> , 2018, 115, 126-138.                      | 1.7  | 61        |
| 132 | Integrating high-throughput screening and sequencing for monoclonal antibody discovery and engineering. <i>Immunology</i> , 2018, 153, 31-41.                                                                          | 2.0  | 72        |



| #   | ARTICLE                                                                                                                                                                                                         | IF   | CITATIONS |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 133 | Monoclonal antibodies: technologies for early discovery and engineering. <i>Critical Reviews in Biotechnology</i> , 2018, 38, 394-408.                                                                          | 5.1  | 61        |
| 134 | Suppression of Hydrophobicity and Optimizations of a Ligand-Immobilization for Effective Affinity Chromatography Using a Spongy Monolith. <i>Chromatography</i> , 2018, 39, 113-118.                            | 0.8  | 4         |
| 135 | Advances and challenges in therapeutic monoclonal antibodies drug development. <i>Brazilian Journal of Pharmaceutical Sciences</i> , 2018, 54, .                                                                | 1.2  | 23        |
| 136 | Principles of Immunotherapy: Implications for Treatment Strategies in Cancer and Infectious Diseases. <i>Frontiers in Microbiology</i> , 2018, 9, 3158.                                                         | 1.5  | 66        |
| 137 | Site-specific chelator-antibody conjugation for PET and SPECT imaging with radiometals. <i>Drug Discovery Today: Technologies</i> , 2018, 30, 91-104.                                                           | 4.0  | 49        |
| 138 | p95HER2â€T cell bispecific antibody for breast cancer treatment. <i>Science Translational Medicine</i> , 2018, 10, .                                                                                            | 5.8  | 59        |
| 139 | A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. <i>Cell</i> , 2018, 175, 313-326.                                                                                                  | 13.5 | 985       |
| 140 | OptMAVEn-2.0: De novo Design of Variable Antibody Regions Against Targeted Antigen Epitopes. <i>Antibodies</i> , 2018, 7, 23.                                                                                   | 1.2  | 42        |
| 141 | Diosgenin promotes antitumor immunity and PD-1 antibody efficacy against melanoma by regulating intestinal microbiota. <i>Cell Death and Disease</i> , 2018, 9, 1039.                                           | 2.7  | 68        |
| 142 | Molecular imaging to enlighten cancer immunotherapies and underlying involved processes. <i>Cancer Treatment Reviews</i> , 2018, 70, 232-244.                                                                   | 3.4  | 36        |
| 143 | Half-Chain Cetuximab Nanoconjugates Allow Multitarget Therapy of Triple Negative Breast Cancer. <i>Bioconjugate Chemistry</i> , 2018, 29, 3817-3832.                                                            | 1.8  | 14        |
| 144 | The Augmenting Effects of the tDNA Insulator on Stable Expression of Monoclonal Antibody in Chinese Hamster Ovary Cells. <i>Monoclonal Antibodies in Immunodiagnosis and Immunotherapy</i> , 2018, 37, 200-206. | 0.8  | 6         |
| 145 | Targeted Intracellular Delivery of Antibodies: The State of the Art. <i>Frontiers in Pharmacology</i> , 2018, 9, 1208.                                                                                          | 1.6  | 144       |
| 146 | Bypassing Endocytosis: Direct Cytosolic Delivery of Proteins. <i>Journal of the American Chemical Society</i> , 2018, 140, 15986-15996.                                                                         | 6.6  | 158       |
| 147 | Screening Strategies for the Discovery of Ion Channel Monoclonal Antibodies. <i>Current Protocols in Pharmacology</i> , 2018, 82, e44.                                                                          | 4.0  | 5         |
| 148 | Nanomedicines for developing cancer nanotherapeutics: from benchtop to bedside and beyond. <i>Applied Microbiology and Biotechnology</i> , 2018, 102, 9449-9470.                                                | 1.7  | 54        |
| 149 | Generation of an anti-desmoglein 3 antibody without pathogenic activity of pemphigus vulgaris for therapeutic application to squamous cell carcinoma. <i>Journal of Biochemistry</i> , 2018, 164, 471-481.      | 0.9  | 4         |
| 150 | Monoclonal Antibody Capture and Analysis Using Porous Membranes Containing Immobilized Peptide Mimotopes. <i>Analytical Chemistry</i> , 2018, 90, 12161-12167.                                                  | 3.2  | 16        |

| #   | ARTICLE                                                                                                                                                                                                                                                          | IF  | CITATIONS |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 151 | Fc Engineering: Tailored Synthetic Human IgG1-Fc Repertoire for High-Affinity Interaction with FcRn at pH 6.0. <i>Methods in Molecular Biology</i> , 2018, 1827, 399-417.                                                                                        | 0.4 | 1         |
| 152 | High Affinity Maturated Human Antibodies from Na <sup>-</sup> ve and Synthetic Antibody Repertoires. , 2018, , .                                                                                                                                                 |     | 0         |
| 153 | Therapeutic target database update 2018: enriched resource for facilitating bench-to-clinic research of targeted therapeutics. <i>Nucleic Acids Research</i> , 2018, 46, D1121-D1127.                                                                            | 6.5 | 462       |
| 154 | Through the barricades: overcoming the barriers to effective antibody-based cancer therapeutics. <i>Glycobiology</i> , 2018, 28, 697-712.                                                                                                                        | 1.3 | 8         |
| 155 | Neue Methoden und Designprinzipien für zellgängige Peptide. <i>Angewandte Chemie</i> , 2018, 130, 12042-12057.                                                                                                                                                   | 1.6 | 18        |
| 156 | An anti-EGFR- $\alpha$ - $\beta$ cotinine bispecific antibody complexed with cotinine-conjugated duocarmycin inhibits growth of EGFR-positive cancer cells with KRAS mutations. <i>Experimental and Molecular Medicine</i> , 2018, 50, 1-14.                     | 3.2 | 12        |
| 157 | Digesting a Path Forward: The Utility of Collagenase Tumor Treatment for Improved Drug Delivery. <i>Molecular Pharmaceutics</i> , 2018, 15, 2069-2083.                                                                                                           | 2.3 | 94        |
| 158 | Development and validation of a targeted affinity-enrichment and LC-MS/MS proteomics approach for the therapeutic monitoring of adalimumab. <i>Clinica Chimica Acta</i> , 2018, 483, 308-314.                                                                    | 0.5 | 6         |
| 160 | Online Hydrophobic Interaction Chromatography-Mass Spectrometry for the Analysis of Intact Monoclonal Antibodies. <i>Analytical Chemistry</i> , 2018, 90, 7135-7138.                                                                                             | 3.2 | 53        |
| 162 | Structural basis for the recognition of complex-type N-glycans by Endoglycosidase S. <i>Nature Communications</i> , 2018, 9, 1874.                                                                                                                               | 5.8 | 38        |
| 163 | Surface Plasmon Resonance-Based Immunoassays. , 2018, , 129-156.                                                                                                                                                                                                 |     | 7         |
| 164 | Therapeutic Monoclonal Antibodies to Complex Membrane Protein Targets: Antigen Generation and Antibody Discovery Strategies. <i>BioDrugs</i> , 2018, 32, 339-355.                                                                                                | 2.2 | 31        |
| 165 | Unraveling the mysteries of modern size exclusion chromatography - the way to achieve confident characterization of therapeutic proteins. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2018, 1092, 368-378. | 1.2 | 48        |
| 166 | A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity. <i>Journal of Visualized Experiments</i> , 2018, , .                                                                                                                                 | 0.2 | 6         |
| 167 | Development of a Hydrodynamic Cleaning Cycle for Ultrafiltration/Diafiltration Processes Used for Monoclonal Antibody Formulation. <i>Industrial &amp; Engineering Chemistry Research</i> , 2018, 57, 16110-16115.                                               | 1.8 | 4         |
| 168 | Conservation of oncofetal antigens on human embryonic stem cells enables discovery of monoclonal antibodies against cancer. <i>Scientific Reports</i> , 2018, 8, 11608.                                                                                          | 1.6 | 4         |
| 169 | Tumor-Targeting Anti-CD20 Antibodies Mediate In Vitro Expansion of Memory Natural Killer Cells: Impact of CD16 Affinity Ligation Conditions and In Vivo Priming. <i>Frontiers in Immunology</i> , 2018, 9, 1031.                                                 | 2.2 | 22        |
| 170 | Construction and Characterization of a Humanized Anti-Epstein-Barr Virus gp350 Antibody with Neutralizing Activity in Cell Culture. <i>Cancers</i> , 2018, 10, 112.                                                                                              | 1.7 | 8         |

| #   | ARTICLE                                                                                                                                                                                                                    | IF  | CITATIONS |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 171 | Construction of Anti-HER2 Recombinants as Targeting Modules for a Drug-delivery System Against HER2-positive Cells. <i>Anticancer Research</i> , 2018, 38, 4319-4325.                                                      | 0.5 | 6         |
| 172 | Anti-ADAM17 monoclonal antibody MEDI3622 increases IFN $\gamma$ production by human NK cells in the presence of antibody-bound tumor cells. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1407-1416.                 | 2.0 | 37        |
| 173 | Production of a mouse monoclonal IgM antibody that targets the carbohydrate Thomsen-nouveau cancer antigen resulting in in vivo and in vitro tumor killing. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1437-1447. | 2.0 | 11        |
| 174 | Emerging Methods and Design Principles for Cell-Penetrant Peptides. <i>Angewandte Chemie - International Edition</i> , 2018, 57, 11868-11881.                                                                              | 7.2 | 116       |
| 175 | Antineoplastic activity of linear leucine homodipeptides and their potential mechanisms of action. <i>Anti-Cancer Drugs</i> , 2018, 29, 503-512.                                                                           | 0.7 | 0         |
| 176 | Pharmacological Profile and Pharmacogenomics of Anti-Cancer Drugs Used for Targeted Therapy. <i>Current Cancer Drug Targets</i> , 2018, 18, 499-511.                                                                       | 0.8 | 48        |
| 177 | Overlooked benefits of using polyclonal antibodies. <i>BioTechniques</i> , 2018, 65, 127-136.                                                                                                                              | 0.8 | 83        |
| 178 | Epitope-specific affinity maturation improved stability of potent protease inhibitory antibodies. <i>Biotechnology and Bioengineering</i> , 2018, 115, 2673-2682.                                                          | 1.7 | 4         |
| 179 | Nanoengineering of Poly(ethylene glycol) Particles for Stealth and Targeting. <i>Langmuir</i> , 2018, 34, 10817-10827.                                                                                                     | 1.6 | 55        |
| 180 | Addressing Cancer Chemotherapeutic Toxicity, Resistance, and Heterogeneity: Novel Theranostic Use of DNA-Encoded Small Molecule Libraries. <i>BioEssays</i> , 2018, 40, 1800057.                                           | 1.2 | 13        |
| 181 | A cell-penetrating whole molecule antibody targeting intracellular HBx suppresses hepatitis B virus via TRIM21-dependent pathway. <i>Theranostics</i> , 2018, 8, 549-562.                                                  | 4.6 | 51        |
| 182 | Anti-PSMA/CD3 Bispecific Antibody Delivery and Antitumor Activity Using a Polymeric Depot Formulation. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1927-1940.                                                         | 1.9 | 39        |
| 183 | Tutorial on Monoclonal Antibody Pharmacokinetics and Its Considerations in Early Development. <i>Clinical and Translational Science</i> , 2018, 11, 540-552.                                                               | 1.5 | 168       |
| 184 | Therapeutic Monoclonal Antibodies as Immunomodulators and Anti-Cancer Agents: Development, Evidence of Efficacy, Mechanisms of Actions, Adverse Effects. , 2018, , 291-341.                                                |     | 3         |
| 185 | Genome-scale identification of cellular pathways required for cell surface recognition. <i>Genome Research</i> , 2018, 28, 1372-1382.                                                                                      | 2.4 | 29        |
| 186 | Displacement Affinity Release of Antibodies from Injectable Hydrogels. <i>ACS Applied Materials &amp; Interfaces</i> , 2019, 11, 30648-30660.                                                                              | 4.0 | 11        |
| 187 | In vivo surveillance and elimination of teratoma-forming human embryonic stem cells with monoclonal antibody 2448 targeting annexin A2. <i>Biotechnology and Bioengineering</i> , 2019, 116, 2996-3005.                    | 1.7 | 13        |
| 188 | IgM Antibodies Can Access Cryptic Antigens Denied to IgG: Hypothesis on Novel Binding Mechanism. <i>Frontiers in Immunology</i> , 2019, 10, 1820.                                                                          | 2.2 | 4         |

| #   | ARTICLE                                                                                                                                                                                                                                        | IF  | CITATIONS |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 189 | Folate Receptor $\alpha$ -Targeted $^{89}\text{Zr}$ -M9346A Immuno-PET for Image-Guided Intervention with Mirvetuximab Soravtansine in Triple-Negative Breast Cancer. <i>Molecular Pharmaceutics</i> , 2019, 16, 3996-4006.                    | 2.3 | 12        |
| 190 | Quantitation of Super Basic Peptides in Biological Matrices by a Generic Perfluoropentanoic Acid-Based Liquid Chromatography-Mass Spectrometry Method. <i>Journal of the American Society for Mass Spectrometry</i> , 2019, 30, 1779-1789.     | 1.2 | 3         |
| 191 | Exploring the analytical power of the QTOF MS platform to assess monoclonal antibodies quality attributes. <i>PLoS ONE</i> , 2019, 14, e0219156.                                                                                               | 1.1 | 9         |
| 192 | Overview of Current Targeted Anti-Cancer Drugs for Therapy in Onco-Hematology. <i>Medicina (Lithuania)</i> , 2019, 55, 414.                                                                                                                    | 0.8 | 18        |
| 193 | Signal Transduction in Radiation Oncology. , 2019, , 1-17.                                                                                                                                                                                     |     | 0         |
| 194 | Site-Specific Encoding of Photoactivity in Antibodies Enables Light-Mediated Antibody-Antigen Binding on Live Cells. <i>Angewandte Chemie</i> , 2019, 131, 18154-18161.                                                                        | 1.6 | 10        |
| 195 | One-step site-specific antibody fragment auto-conjugation using SNAP-tag technology. <i>Nature Protocols</i> , 2019, 14, 3101-3125.                                                                                                            | 5.5 | 19        |
| 196 | Site-Specific Encoding of Photoactivity in Antibodies Enables Light-Mediated Antibody-Antigen Binding on Live Cells. <i>Angewandte Chemie - International Edition</i> , 2019, 58, 17986-17993.                                                 | 7.2 | 38        |
| 197 | Fibroblast growth factor receptor inhibitors: patent review (2015-2019). <i>Expert Opinion on Therapeutic Patents</i> , 2019, 29, 965-977.                                                                                                     | 2.4 | 11        |
| 198 | Deep sequencing of B cell receptor repertoire. <i>BMB Reports</i> , 2019, 52, 540-547.                                                                                                                                                         | 1.1 | 17        |
| 199 | Role of amphiphilic [metal:chelator] complexes in a non-chromatographic antibody purification platform. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2019, 1133, 121830.                  | 1.2 | 7         |
| 200 | Antibody discovery and engineering by enhanced CRISPR-Cas9 integration of variable gene cassette libraries in mammalian cells. <i>MAbs</i> , 2019, 11, 1367-1380.                                                                              | 2.6 | 24        |
| 201 | A Tridimensional Model for NK Cell-Mediated ADCC of Follicular Lymphoma. <i>Frontiers in Immunology</i> , 2019, 10, 1943.                                                                                                                      | 2.2 | 22        |
| 202 | Antibody-drug conjugates for cancer. <i>Lancet, The</i> , 2019, 394, 793-804.                                                                                                                                                                  | 6.3 | 425       |
| 203 | Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan (DS-8201a) and (Vic)-Trastuzumab Duocarmazine (SYD985). <i>European Journal of Medicinal Chemistry</i> , 2019, 183, 111682. | 2.6 | 102       |
| 204 | Distributed optimal control of a tumor growth treatment model with cross-diffusion effect. <i>European Physical Journal Plus</i> , 2019, 134, 1.                                                                                               | 1.2 | 13        |
| 205 | HCV p7 as a novel vaccine-target inducing multifunctional CD4+ and CD8+ T-cells targeting liver cells expressing the viral antigen. <i>Scientific Reports</i> , 2019, 9, 14085.                                                                | 1.6 | 21        |
| 206 | The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2019, 25, 3176-3187.                                                                                            | 3.2 | 156       |

| #   | ARTICLE                                                                                                                                                                                                                                                 | IF   | CITATIONS |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 207 | Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies. , 2019, 7, 29.                                                                                                                                                    |      | 63        |
| 208 | Fighting Staphylococcus aureus Biofilms with Monoclonal Antibodies. Trends in Microbiology, 2019, 27, 303-322.                                                                                                                                          | 3.5  | 62        |
| 209 | CD81 is a novel immunotherapeutic target for B cell lymphoma. Journal of Experimental Medicine, 2019, 216, 1497-1508.                                                                                                                                   | 4.2  | 31        |
| 210 | Intracellular Delivery of an Antibody Targeting Gasdermin-B Reduces HER2 Breast Cancer Aggressiveness. Clinical Cancer Research, 2019, 25, 4846-4858.                                                                                                   | 3.2  | 79        |
| 211 | Immunoglobulins as Radiopharmaceutical Vectors. , 2019, , 163-179.                                                                                                                                                                                      |      | 3         |
| 212 | Cancer stem cell immunology and immunotherapy: Harnessing the immune system against cancer's source. Progress in Molecular Biology and Translational Science, 2019, 164, 119-188.                                                                       | 0.9  | 32        |
| 213 | An Engineered Human Fc variant With Exquisite Selectivity for Fcγ3RIIIaV158 Reveals That Ligation of Fcγ3RIIIa Mediates Potent Antibody Dependent Cellular Phagocytosis With GM-CSF-Differentiated Macrophages. Frontiers in Immunology, 2019, 10, 562. | 2.2  | 17        |
| 214 | Nanomedicines for improved targetability to inflamed synovium for treatment of rheumatoid arthritis: Multi-functionalization as an emerging strategy to optimize therapeutic efficacy. Journal of Controlled Release, 2019, 303, 181-208.               | 4.8  | 51        |
| 215 | A Novel Fully Human Antibody targeting Extracellular Domain of PSMA Inhibits Tumor Growth in Prostate Cancer. Molecular Cancer Therapeutics, 2019, 18, 1289-1301.                                                                                       | 1.9  | 8         |
| 216 | Bioactive cell penetrating peptides and proteins in cancer: a bright future ahead. Current Opinion in Pharmacology, 2019, 47, 133-140.                                                                                                                  | 1.7  | 35        |
| 217 | Bioprocess development of a stable FUT8 <sup>Δ</sup> -CHO cell line to produce defucosylated anti-HER2 antibody. Bioprocess and Biosystems Engineering, 2019, 42, 1263-1271.                                                                            | 1.7  | 16        |
| 218 | Mitochondria <sup>Δ</sup> -Targeting, Intracellular Delivery of Native Proteins Using Biodegradable Silica Nanoparticles. Angewandte Chemie, 2019, 131, 7739-7743.                                                                                      | 1.6  | 25        |
| 219 | Mitochondria <sup>Δ</sup> -Targeting, Intracellular Delivery of Native Proteins Using Biodegradable Silica Nanoparticles. Angewandte Chemie - International Edition, 2019, 58, 7657-7661.                                                               | 7.2  | 120       |
| 220 | T-cell Activating Tribodies as a Novel Approach for Efficient Killing of ErbB2-positive Cancer Cells. Journal of Immunotherapy, 2019, 42, 1-10.                                                                                                         | 1.2  | 11        |
| 221 | IgE Antibodies: From Structure to Function and Clinical Translation. Antibodies, 2019, 8, 19.                                                                                                                                                           | 1.2  | 62        |
| 222 | Novel immunotherapeutic approaches for hepatocellular carcinoma treatment. Expert Review of Clinical Pharmacology, 2019, 12, 453-470.                                                                                                                   | 1.3  | 28        |
| 223 | &lt;p&gt;Nonspecific immunoglobulin G is effective in preventing and treating cancer in mice&lt;/p&gt;. Cancer Management and Research, 2019, Volume 11, 2073-2085.                                                                                     | 0.9  | 12        |
| 224 | Vesicular Antibodies: A Bioactive Multifunctional Combination Platform for Targeted Therapeutic Delivery and Cancer Immunotherapy. Advanced Materials, 2019, 31, e1808294.                                                                              | 11.1 | 63        |

| #   | ARTICLE                                                                                                                                                                           | IF   | CITATIONS |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 225 | Quadrupole Dalton-Based Controlled Proteolysis Method for Characterization of Higher Order Protein Structure. <i>Analytical Chemistry</i> , 2019, 91, 5339-5345.                  | 3.2  | 6         |
| 226 | Canine CD117-Specific Antibodies with Diverse Binding Properties Isolated from a Phage Display Library Using Cell-Based Biopanning. <i>Antibodies</i> , 2019, 8, 15.              | 1.2  | 3         |
| 227 | A fully human anti-IL-7R $\alpha$ antibody promotes antitumor activity against T-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2019, 33, 2155-2168.                        | 3.3  | 41        |
| 228 | Multifunctional Scaffolds for Assembling Cancer-Targeting Immune Stimulators Using Chemoselective Ligations. <i>Frontiers in Chemistry</i> , 2019, 7, 113.                        | 1.8  | 3         |
| 229 | Synthetic Lethality in Lung Cancer – From the Perspective of Cancer Genomics. <i>Medicines (Basel)</i> , 2019, 8, 107.                                                            | 0.7  | 6         |
| 230 | Weaponizing T-cell receptors through molecular engineering. <i>Journal of Biological Chemistry</i> , 2019, 294, 5805-5806.                                                        | 1.6  | 2         |
| 231 | Multiscale engineering of immune cells and lymphoid organs. <i>Nature Reviews Materials</i> , 2019, 4, 355-378.                                                                   | 23.3 | 55        |
| 232 | CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering. <i>Haematologica</i> , 2019, 104, 1841-1852.                                                 | 1.7  | 38        |
| 233 | Emerging technologies in protein interface engineering for biomedical applications. <i>Current Opinion in Biotechnology</i> , 2019, 60, 82-88.                                    | 3.3  | 7         |
| 234 | Emerging Nano- and Microapproaches for Cancer Immunotherapy. <i>Advanced Science</i> , 2019, 6, 1801847.                                                                          | 5.6  | 136       |
| 235 | Systemic Delivery of Monoclonal Antibodies to the Central Nervous System for Brain Tumor Therapy. <i>Advanced Materials</i> , 2019, 31, e1805697.                                 | 11.1 | 84        |
| 236 | What Does the Pipeline Promise about Upcoming Biosimilar Antibodies in Oncology?. <i>Breast Care</i> , 2019, 14, 10-16.                                                           | 0.8  | 18        |
| 237 | Production of functional recombinant cyclic citrullinated peptide monoclonal antibody in transgenic rice cell suspension culture. <i>Transgenic Research</i> , 2019, 28, 177-188. | 1.3  | 15        |
| 238 | Memory NK Cell Features Exploitable in Anticancer Immunotherapy. <i>Journal of Immunology Research</i> , 2019, 2019, 1-8.                                                         | 0.9  | 15        |
| 239 | Antibody Fragments as Potential Biopharmaceuticals for Cancer Therapy: Success and Limitations. <i>Current Medicinal Chemistry</i> , 2019, 26, 396-426.                           | 1.2  | 67        |
| 240 | Current and Future Treatment Strategies for Rhabdomyosarcoma. <i>Frontiers in Oncology</i> , 2019, 9, 1458.                                                                       | 1.3  | 100       |
| 241 | Opportunities for Antibody Discovery Using Human Pluripotent Stem Cells: Conservation of Oncofetal Targets. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5752.  | 1.8  | 4         |
| 242 | On-target restoration of a split T cell-engaging antibody for precision immunotherapy. <i>Nature Communications</i> , 2019, 10, 5387.                                             | 5.8  | 38        |

| #   | ARTICLE                                                                                                                                                                                          | IF  | CITATIONS |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 243 | Comprehensive characterization of monoclonal antibody by Fourier transform ion cyclotron resonance mass spectrometry. <i>MAbs</i> , 2019, 11, 106-115.                                           | 2.6 | 50        |
| 244 | A Suicide Switch Directly Eliminates Intracellular scFv Oligomers in the Cytoplasm of Mammalian Cells. <i>Biotechnology Journal</i> , 2019, 14, e1800350.                                        | 1.8 | 5         |
| 245 | 3D in vitro models of tumors expressing EGFR family receptors: a potent tool for studying receptor biology and targeted drug development. <i>Drug Discovery Today</i> , 2019, 24, 99-111.        | 3.2 | 11        |
| 246 | A Hybrid Platform Based on a Bispecific Peptide-Antibody Complex for Targeted Cancer Therapy. <i>Angewandte Chemie - International Edition</i> , 2019, 58, 2005-2010.                            | 7.2 | 9         |
| 247 | Structural Analysis of Monoclonal Antibodies by Ultrahigh Resolution MALDI In-Source Decay FT-ICR Mass Spectrometry. <i>Analytical Chemistry</i> , 2019, 91, 2079-2085.                          | 3.2 | 48        |
| 248 | Improved Efficacy of Antibody Cancer Immunotherapeutics through Local and Sustained Delivery. <i>ChemBioChem</i> , 2019, 20, 747-753.                                                            | 1.3 | 12        |
| 249 | A general platform for antibody purification utilizing engineered-micelles. <i>MAbs</i> , 2019, 11, 583-592.                                                                                     | 2.6 | 8         |
| 250 | A Hybrid Platform Based on a Bispecific Peptide-Antibody Complex for Targeted Cancer Therapy. <i>Angewandte Chemie</i> , 2019, 131, 2027-2032.                                                   | 1.6 | 4         |
| 251 | Roadmap for the Development and Clinical Translation of Optical Tracers Cetuximab-800CW and Trastuzumab-800CW. <i>Journal of Nuclear Medicine</i> , 2019, 60, 418-423.                           | 2.8 | 22        |
| 253 | Trehalose Limits Fragment Antibody Aggregation and Influences Charge Variant Formation in Spray-Dried Formulations at Elevated Temperatures. <i>Molecular Pharmaceutics</i> , 2019, 16, 349-358. | 2.3 | 9         |
| 254 | High-Throughput Antibody Structure Modeling and Design Using ABodyBuilder. <i>Methods in Molecular Biology</i> , 2019, 1851, 367-380.                                                            | 0.4 | 3         |
| 255 | Computational Methods in Protein Evolution. <i>Methods in Molecular Biology</i> , 2019, , .                                                                                                      | 0.4 | 1         |
| 256 | Evaluation of a novel monoclonal antibody mAb109 by immuno-PET/fluorescent imaging for noninvasive lung adenocarcinoma diagnosis. <i>Acta Pharmacologica Sinica</i> , 2020, 41, 101-109.         | 2.8 | 6         |
| 257 | Design and characterization of novel dual Fc antibody with enhanced avidity for Fc receptors. <i>Proteins: Structure, Function and Bioinformatics</i> , 2020, 88, 689-697.                       | 1.5 | 6         |
| 258 | Development of therapeutic antibodies for the treatment of diseases. <i>Journal of Biomedical Science</i> , 2020, 27, 1.                                                                         | 2.6 | 1,277     |
| 259 | Targeted Host Cell Protein Quantification by LC-MRM Enables Biologics Processing and Product Characterization. <i>Analytical Chemistry</i> , 2020, 92, 1007-1015.                                | 3.2 | 29        |
| 260 | Towards a new avenue for producing therapeutic proteins: Microalgae as a tempting green biofactory. <i>Biotechnology Advances</i> , 2020, 40, 107499.                                            | 6.0 | 28        |
| 261 | PD-1 disrupted CAR-T cells in the treatment of solid tumors: Promises and challenges. <i>Biomedicine and Pharmacotherapy</i> , 2020, 121, 109625.                                                | 2.5 | 92        |



| #   | ARTICLE                                                                                                                                                                                                         | IF  | CITATIONS |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 262 | Competition-Based Universal Photonic Crystal Biosensors by Using Antibody-Antigen Interaction. <i>Journal of the American Chemical Society</i> , 2020, 142, 417-423.                                            | 6.6 | 68        |
| 263 | Homogenous Scavenging Resolves Low-Purification Yield/Selectivity Caused by Secondary Binding of Protein-A to Antigen-Binding Antibody Fragments. <i>Biomacromolecules</i> , 2020, 21, 825-829.                 | 2.6 | 1         |
| 264 | Inhibition of Osteoclastogenesis by the RNA-Binding Protein QK15: a Novel Approach to Protect from Bone Resorption. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 753-765.                            | 3.1 | 11        |
| 265 | Stanniocalcin-1 protein expression profile and mechanisms in proliferation and cell death pathways in prostate cancer. <i>Molecular and Cellular Endocrinology</i> , 2020, 502, 110659.                         | 1.6 | 3         |
| 266 | Defining the right diluent for intravenous infusion of therapeutic antibodies. <i>MAbs</i> , 2020, 12, 1685814.                                                                                                 | 2.6 | 18        |
| 267 | UCNP-based Photoluminescent Nanomedicines for Targeted Imaging and Theranostics of Cancer. <i>Molecules</i> , 2020, 25, 4302.                                                                                   | 1.7 | 16        |
| 268 | Antibody-Drug Conjugates for Cancer Therapy. <i>Molecules</i> , 2020, 25, 4764.                                                                                                                                 | 1.7 | 187       |
| 269 | A microfluidic device for differential capture of heterogeneous rare tumor cells with epithelial and mesenchymal phenotypes. <i>Analytica Chimica Acta</i> , 2020, 1129, 1-11.                                  | 2.6 | 8         |
| 270 | Rapid and sensitive large-scale screening of low affinity extracellular receptor protein interactions by using reaction induced inhibition of Gaussia luciferase. <i>Scientific Reports</i> , 2020, 10, 10522.  | 1.6 | 8         |
| 271 | Cell-Permeant Bioadaptors for Cytosolic Delivery of Native Antibodies: A Mix-and-Go Approach. <i>ACS Central Science</i> , 2020, 6, 2362-2376.                                                                  | 5.3 | 39        |
| 272 | Recent progress in the molecular imaging of therapeutic monoclonal antibodies. <i>Journal of Pharmaceutical Analysis</i> , 2020, 10, 397-413.                                                                   | 2.4 | 16        |
| 273 | Past, Present, and Future of Anticancer Nanomedicine. <i>International Journal of Nanomedicine</i> , 2020, Volume 15, 5719-5743.                                                                                | 3.3 | 23        |
| 274 | Rapid isolation of antigen-specific B-cells using droplet microfluidics. <i>RSC Advances</i> , 2020, 10, 27006-27013.                                                                                           | 1.7 | 30        |
| 275 | Insights into the Mechanism of Action of Highly Diluted Biologics. <i>Journal of Immunology</i> , 2020, 205, 1345-1354.                                                                                         | 0.4 | 48        |
| 276 | A general evidence-based sequence variant control limit for recombinant therapeutic protein development. <i>MAbs</i> , 2020, 12, 1791399.                                                                       | 2.6 | 11        |
| 277 | Improved Detection of in vivo Human NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity Using a Novel NOG-FcγR-Deficient Human IL-15 Transgenic Mouse. <i>Frontiers in Immunology</i> , 2020, 11, 532684. | 2.2 | 10        |
| 278 | Immunotoxin Screening System: A Rapid and Direct Approach to Obtain Functional Antibodies with Internalization Capacities. <i>Toxins</i> , 2020, 12, 658.                                                       | 1.5 | 14        |
| 279 | Interaction between Immunotherapy and Antiangiogenic Therapy for Cancer. <i>Molecules</i> , 2020, 25, 3900.                                                                                                     | 1.7 | 21        |



| #   | ARTICLE                                                                                                                                                                                                                 | IF  | CITATIONS |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 280 | Therapeutic efficacy and safety of a human fusion construct targeting the TWEAK receptor Fn14 and containing a modified granzyme B. , 2020, 8, e001138.                                                                 |     | 4         |
| 281 | Glycosylation-dependent opsonophagocytic activity of staphylococcal protein A antibodies. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 22992-23000.                      | 3.3 | 19        |
| 282 | Phage Display Derived Monoclonal Antibodies: From Bench to Bedside. Frontiers in Immunology, 2020, 11, 1986.                                                                                                            | 2.2 | 146       |
| 283 | Immune-based Therapies for Hematological Malignancies: An Update by the EHA SWG on Immunotherapy of Hematological Malignancies. HemaSphere, 2020, 4, e423.                                                              | 1.2 | 4         |
| 284 | CD38: targeted therapy in multiple myeloma and therapeutic potential for solid cancers. Expert Opinion on Investigational Drugs, 2020, 29, 1295-1308.                                                                   | 1.9 | 17        |
| 285 | The Role of Complement in the Mechanism of Action of Therapeutic Anti-Cancer mAbs. Antibodies, 2020, 9, 58.                                                                                                             | 1.2 | 41        |
| 286 | Liposome-Based Drug Delivery Systems in Cancer Immunotherapy. Pharmaceutics, 2020, 12, 1054.                                                                                                                            | 2.0 | 77        |
| 287 | Recent Advances in Studying Interfacial Adsorption of Bioengineered Monoclonal Antibodies. Molecules, 2020, 25, 2047.                                                                                                   | 1.7 | 20        |
| 288 | Robust Strategy for Antibody-Polymer-Drug Conjugation: Significance of Conjugating Orientation and Linker Charge on Targeting Ability. ACS Applied Materials & Interfaces, 2020, 12, 23717-23725.                       | 4.0 | 10        |
| 289 | Influence of Innate Immunity on Cancer Cell Stemness. International Journal of Molecular Sciences, 2020, 21, 3352.                                                                                                      | 1.8 | 20        |
| 290 | Hybridoma technology a versatile method for isolation of monoclonal antibodies, its applicability across species, limitations, advancement and future perspectives. International Immunopharmacology, 2020, 85, 106639. | 1.7 | 116       |
| 291 | Quantitative Analysis of Antibody Survival across the Infant Digestive Tract Using Mass Spectrometry with Parallel Reaction Monitoring. Foods, 2020, 9, 759.                                                            | 1.9 | 4         |
| 292 | EM2D9, A monoclonal antibody against integrin $\alpha 5 \beta 1$ , has potent antitumor activity on endometrial cancer in vitro and in vivo. Cancer Letters, 2020, 483, 66-74.                                          | 3.2 | 5         |
| 293 | HIV-1 fusion inhibitors targeting the membrane-proximal external region of Env spikes. Nature Chemical Biology, 2020, 16, 529-537.                                                                                      | 3.9 | 28        |
| 294 | A metabolic network-based approach for developing feeding strategies for CHO cells to increase monoclonal antibody production. Bioprocess and Biosystems Engineering, 2020, 43, 1381-1389.                              | 1.7 | 36        |
| 295 | Exploiting antibody biology for the treatment of cancer. Immunotherapy, 2020, 12, 255-267.                                                                                                                              | 1.0 | 7         |
| 296 | Screening Antibody Libraries with Colony Assay Using scFv-Alkaline Phosphatase Fusion Proteins. Molecules, 2020, 25, 2905.                                                                                              | 1.7 | 4         |
| 297 | Nanomedicine and Onco-Immunotherapy: From the Bench to Bedside to Biomarkers. Nanomaterials, 2020, 10, 1274.                                                                                                            | 1.9 | 26        |

| #   | ARTICLE                                                                                                                                                                                 | IF  | CITATIONS |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 298 | Development of Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer: An Update. <i>Biomolecules</i> , 2020, 10, 934.                                                     | 1.8 | 10        |
| 299 | Bidirectional Crosstalk Between Cancer Stem Cells and Immune Cell Subsets. <i>Frontiers in Immunology</i> , 2020, 11, 140.                                                              | 2.2 | 69        |
| 300 | A Plug-and-Play Approach for the <i>De Novo</i> Generation of Dually Functionalized Bispecifics. <i>Bioconjugate Chemistry</i> , 2020, 31, 520-529.                                     | 1.8 | 31        |
| 301 | Improvement of Intracellular Traffic System by Overexpression of KDEL Receptor 1 in Antibody-Producing CHO Cells. <i>Biotechnology Journal</i> , 2020, 15, 1900352.                     | 1.8 | 7         |
| 303 | Antibody Conjugates-Recent Advances and Future Innovations. <i>Antibodies</i> , 2020, 9, 2.                                                                                             | 1.2 | 75        |
| 304 | Cyto-Mine: An Integrated, Picodroplet System for High-Throughput Single-Cell Analysis, Sorting, Dispensing, and Monoclonality Assurance. <i>SLAS Technology</i> , 2020, 25, 177-189.    | 1.0 | 27        |
| 305 | Heavy chain dimers stabilized by disulfide bonds are required to promote in vitro assembly of trastuzumab. <i>BMC Molecular and Cell Biology</i> , 2020, 21, 2.                         | 1.0 | 5         |
| 306 | Construction of Novel Bispecific Single-Domain Antibodies (BiSdAbs) with Potent Antiangiogenic Activities. <i>Pharmaceutical Fronts</i> , 2020, 02, e64-e76.                            | 0.4 | 3         |
| 307 | A Fluorescence-Based Wireless Capsule Endoscopy System for Detecting Colorectal Cancer. <i>Cancers</i> , 2020, 12, 890.                                                                 | 1.7 | 18        |
| 308 | 5- <i>Arylidene</i> -2-(4-hydroxyphenyl)aminothiazol-4(5 H)-ones with selective inhibitory activity against some leukemia cell lines. <i>Archiv Der Pharmazie</i> , 2021, 354, 2000342. | 2.1 | 5         |
| 309 | Tumor-Targeting Liposomes with Transient Holes Allowing Intact Rituximab Internally. <i>Biomacromolecules</i> , 2021, 22, 723-731.                                                      | 2.6 | 13        |
| 310 | Nonionic detergent micelle aggregates: An economical alternative to protein A chromatography. <i>New Biotechnology</i> , 2021, 61, 90-98.                                               | 2.4 | 6         |
| 311 | Effects of autophagy inducers on recombinant antibody production in insect cells. <i>Cytotechnology</i> , 2021, 73, 299-305.                                                            | 0.7 | 2         |
| 312 | Treating Parkinson's Disease with Antibodies: Previous Studies and Future Directions. <i>Journal of Parkinson's Disease</i> , 2021, 11, 71-92.                                          | 1.5 | 21        |
| 313 | Approaching sites of action of drugs in clinical pharmacology: New analytical options and their challenges. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 858-874.        | 1.1 | 9         |
| 314 | Nano-immunotherapy: Overcoming tumour immune evasion. <i>Seminars in Cancer Biology</i> , 2021, 69, 238-248.                                                                            | 4.3 | 47        |
| 315 | Antibody-drug conjugates for lung cancer in the era of personalized oncology. <i>Seminars in Cancer Biology</i> , 2021, 69, 268-278.                                                    | 4.3 | 17        |
| 316 | Hydrogel Microsphere Encapsulation Enhances the Flow Properties of Monoclonal Antibody Crystal Formulations. <i>Advanced Therapeutics</i> , 2021, 4, 2000216.                           | 1.6 | 5         |

| #   | ARTICLE                                                                                                                                                                                                                                                                                 | IF  | CITATIONS |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 317 | Analysis of the tumor microenvironment and anti-tumor efficacy of subcutaneous vs systemic delivery of the bifunctional agent bintrafusp alfa. <i>Oncolimmunology</i> , 2021, 10, 1915561.                                                                                              | 2.1 | 5         |
| 318 | <i>In vivo</i> trafficking of a tumor-targeting IgE antibody: molecular imaging demonstrates rapid hepatobiliary clearance compared to IgG counterpart. <i>Oncolimmunology</i> , 2021, 10, 1966970.                                                                                     | 2.1 | 2         |
| 319 | Translational aspects of biologicals: monoclonal antibodies and antibody-drug conjugates as examples. , 2021, , 329-350.                                                                                                                                                                |     | 0         |
| 320 | Therapeutic Approaches to Employ Monoclonal Antibody for Cancer Treatment. <i>Advances in Medical Diagnosis, Treatment, and Care</i> , 2021, , 42-88.                                                                                                                                   | 0.1 | 0         |
| 321 | Immune Stimulating Antibody-Photosensitizer Conjugates via Fc-Mediated Dendritic Cell Phagocytosis and Phototriggered Immunogenic Cell Death for KRAS-Mutated Pancreatic Cancer Treatment. <i>Small</i> , 2021, 17, e2006650.                                                           | 5.2 | 18        |
| 322 | Novel method for screening functional antibody with comprehensive analysis of its immunoliposome. <i>Scientific Reports</i> , 2021, 11, 4625.                                                                                                                                           | 1.6 | 4         |
| 323 | Strategies to better treat glioblastoma: antiangiogenic agents and endothelial cell targeting agents. <i>Future Medicinal Chemistry</i> , 2021, 13, 393-418.                                                                                                                            | 1.1 | 1         |
| 324 | Alpha-enolase (ENO1), identified as an antigen to monoclonal antibody 12C7, promotes the self-renewal and malignant phenotype of lung cancer stem cells by AMPK/mTOR pathway. <i>Stem Cell Research and Therapy</i> , 2021, 12, 119.                                                    | 2.4 | 8         |
| 325 | Intracellular Delivery of Active Proteins by Polyphosphazene Polymers. <i>Pharmaceutics</i> , 2021, 13, 249.                                                                                                                                                                            | 2.0 | 9         |
| 326 | Identification of Proteolysis Products in Protein Therapeutics through TMPP N-Terminal Tagging and Electron Transfer Dissociation Product Triggered Collisional Induced Dissociation Fragmentation. <i>Journal of the American Society for Mass Spectrometry</i> , 2021, 32, 1936-1944. | 1.2 | 0         |
| 327 | Novel TLR 7/8 agonists for improving NK cell mediated antibody-dependent cellular cytotoxicity (ADCC). <i>Scientific Reports</i> , 2021, 11, 3346.                                                                                                                                      | 1.6 | 17        |
| 328 | Nano-Oncologics: A Tortoise Trail Reaching New Avenues. <i>Advanced Functional Materials</i> , 2021, 31, 2009860.                                                                                                                                                                       | 7.8 | 13        |
| 329 | Bispecific Antibodies in Prostate Cancer Therapy: Current Status and Perspectives. <i>Cancers</i> , 2021, 13, 549.                                                                                                                                                                      | 1.7 | 13        |
| 330 | Targeting chemokines for acute lymphoblastic leukemia therapy. <i>Journal of Hematology and Oncology</i> , 2021, 14, 48.                                                                                                                                                                | 6.9 | 27        |
| 331 | Augmented antibody-based anticancer therapeutics boost neutrophil cytotoxicity. <i>Journal of Clinical Investigation</i> , 2021, 131, .                                                                                                                                                 | 3.9 | 29        |
| 332 | Management of Rhabdomyosarcoma in Pediatric Patients. <i>Surgical Oncology Clinics of North America</i> , 2021, 30, 339-353.                                                                                                                                                            | 0.6 | 10        |
| 333 | Alternative mobile phase additives for the characterization of protein biopharmaceuticals in liquid chromatography - Mass spectrometry. <i>Analytica Chimica Acta</i> , 2021, 1156, 338347.                                                                                             | 2.6 | 14        |
| 334 | Neoantigen: A New Breakthrough in Tumor Immunotherapy. <i>Frontiers in Immunology</i> , 2021, 12, 672356.                                                                                                                                                                               | 2.2 | 115       |

| #   | ARTICLE                                                                                                                                                                                                                      | IF  | CITATIONS |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 335 | Development of an Antigen-Antibody Co-Display System for Detecting Interaction of G-Protein-Coupled Receptors and Single-Chain Variable Fragments. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4711.      | 1.8 | 1         |
| 336 | Switchable CAR-T Cells Outperformed Traditional Antibody-Redirected Therapeutics Targeting Breast Cancers. <i>ACS Synthetic Biology</i> , 2021, 10, 1176-1183.                                                               | 1.9 | 15        |
| 337 | Nanogel-Facilitated Protein Intracellular Specific Degradation through Trim-Away. <i>Advanced Functional Materials</i> , 2021, 31, 2010556.                                                                                  | 7.8 | 20        |
| 339 | Visualization of Intratumor Pharmacokinetics of [fam-] Trastuzumab Deruxtecan (DS-8201a) in HER2 Heterogeneous Model Using Phosphor-integrated Dots Imaging Analysis. <i>Clinical Cancer Research</i> , 2021, 27, 3970-3979. | 3.2 | 15        |
| 340 | Harnessing CD16-Mediated NK Cell Functions to Enhance Therapeutic Efficacy of Tumor-Targeting mAbs. <i>Cancers</i> , 2021, 13, 2500.                                                                                         | 1.7 | 39        |
| 341 | A purification platform for antibodies and derived fragments using a de novo designed affinity adsorbent. <i>Separation and Purification Technology</i> , 2021, 265, 118476.                                                 | 3.9 | 5         |
| 342 | Single Domain Antibodies as Carriers for Intracellular Drug Delivery: A Proof of Principle Study. <i>Biomolecules</i> , 2021, 11, 927.                                                                                       | 1.8 | 2         |
| 343 | Development of Therapeutic Antibodies and Modulating the Characteristics of Therapeutic Antibodies to Maximize the Therapeutic Efficacy. <i>Biotechnology and Bioprocess Engineering</i> , 2021, 26, 295-311.                | 1.4 | 7         |
| 344 | Evaluation of In Vitro Phototoxicity of a Minibody-IR700 Conjugate Using Cell Monolayer and Multicellular Tumor Spheroid Models. <i>Cancers</i> , 2021, 13, 3356.                                                            | 1.7 | 3         |
| 345 | Modified Therapeutic Antibodies: Improving Efficacy. <i>Engineering</i> , 2021, 7, 1529-1540.                                                                                                                                | 3.2 | 3         |
| 346 | Sensitive assay design for detection of anti-drug antibodies to biotherapeutics that lack an immunoglobulin Fc domain. <i>Scientific Reports</i> , 2021, 11, 15467.                                                          | 1.6 | 4         |
| 347 | TNBC: Potential Targeting of Multiple Receptors for a Therapeutic Breakthrough, Nanomedicine, and Immunotherapy. <i>Biomedicines</i> , 2021, 9, 876.                                                                         | 1.4 | 41        |
| 348 | Insights into substrate recognition and specificity for IgG by Endoglycosidase S2. <i>PLoS Computational Biology</i> , 2021, 17, e1009103.                                                                                   | 1.5 | 5         |
| 349 | Influence of Fc Modifications and IgG Subclass on Biodistribution of Humanized Antibodies Targeting L1CAM. <i>Journal of Nuclear Medicine</i> , 2022, 63, 629-636.                                                           | 2.8 | 5         |
| 350 | Acetate decreases PVR/CD155 expression via PI3K/AKT pathway in cancer cells. <i>BMB Reports</i> , 2021, 54, 431-436.                                                                                                         | 1.1 | 9         |
| 351 | Functional Characterization of Pembrolizumab Produced in <i>Nicotiana benthamiana</i> Using a Rapid Transient Expression System. <i>Frontiers in Plant Science</i> , 2021, 12, 736299.                                       | 1.7 | 18        |
| 352 | The EHA Research Roadmap: Immune-based Therapies for Hematological Malignancies. <i>HemaSphere</i> , 2021, 5, e642.                                                                                                          | 1.2 | 2         |
| 353 | A Novel Treatment for Ewing's Sarcoma: Chimeric Antigen Receptor-T Cell Therapy. <i>Frontiers in Immunology</i> , 2021, 12, 707211.                                                                                          | 2.2 | 9         |

| #   | ARTICLE                                                                                                                                                                                                                                                                                           | IF  | CITATIONS |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 354 | Intracellular delivery of anti-BCR/ABL antibody by PLGA nanoparticles suppresses the oncogenesis of chronic myeloid leukemia cells. <i>Journal of Hematology and Oncology</i> , 2021, 14, 139.                                                                                                    | 6.9 | 18        |
| 355 | Genetically Engineered Cellular Membrane Vesicles as Tailorable Shells for Therapeutics. <i>Advanced Science</i> , 2021, 8, e2100460.                                                                                                                                                             | 5.6 | 34        |
| 356 | Immunotoxin IHP25-BT with low immunogenicity and off-target toxicity inhibits the growth and metastasis of trastuzumab-resistant tumor cells. <i>International Journal of Pharmaceutics</i> , 2021, 608, 121081.                                                                                  | 2.6 | 2         |
| 357 | ANO7: Insights into topology, function, and potential applications as a biomarker and immunotherapy target. <i>Tissue and Cell</i> , 2021, 72, 101546.                                                                                                                                            | 1.0 | 7         |
| 358 | Rational design of nanocarriers based on gellan gum/retrograded starch exploiting polyelectrolyte complexation and ionic cross-linking processes: A potential technological platform for oral delivery of bevacizumab. <i>Journal of Drug Delivery Science and Technology</i> , 2021, 66, 102765. | 1.4 | 3         |
| 359 | Bispecific antibodies: A promising entrant in cancer immunotherapy. , 2021, , 233-266.                                                                                                                                                                                                            |     | 2         |
| 360 | Immunotherapy for targeting cancer stem cells in hepatocellular carcinoma. <i>Theranostics</i> , 2021, 11, 3489-3501.                                                                                                                                                                             | 4.6 | 35        |
| 361 | Targeting cancer metastasis with antibody therapeutics. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2021, 13, e1698.                                                                                                                                             | 3.3 | 17        |
| 362 | Potent RBD-specific neutralizing rabbit monoclonal antibodies recognize emerging SARS-CoV-2 variants elicited by DNA prime-protein boost vaccination. <i>Emerging Microbes and Infections</i> , 2021, 10, 1390-1403.                                                                              | 3.0 | 16        |
| 364 | Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease. <i>Cancer Discovery</i> , 2021, 11, 308-325.                                                                                       | 7.7 | 49        |
| 365 | Desirable cytolytic immune effector cell recruitment by interleukin-15 dendritic cells. <i>Oncotarget</i> , 2017, 8, 13652-13665.                                                                                                                                                                 | 0.8 | 18        |
| 366 | Recombinant frizzled1 protein attenuated cardiac hypertrophy after myocardial infarction via the canonical Wnt signaling pathway. <i>Oncotarget</i> , 2018, 9, 3069-3080.                                                                                                                         | 0.8 | 10        |
| 367 | A bi-specific inhibitor targeting IL-17A and MMP-9 reduces invasion and motility in MDA-MB-231 cells. <i>Oncotarget</i> , 2018, 9, 28500-28513.                                                                                                                                                   | 0.8 | 4         |
| 368 | Large-scale in-silico identification of a tumor-specific antigen pool for targeted immunotherapy in triple-negative breast cancer. <i>Oncotarget</i> , 2019, 10, 2515-2529.                                                                                                                       | 0.8 | 11        |
| 369 | Current applications and future prospects of nanotechnology in cancer immunotherapy. <i>Cancer Biology and Medicine</i> , 2019, 16, 487-497.                                                                                                                                                      | 1.4 | 40        |
| 370 | Lessons learned from rindopepimut treatment in patients with EGFRvIII-expressing glioblastoma. <i>Translational Cancer Research</i> , 2018, 7, S510-S513.                                                                                                                                         | 0.4 | 19        |
| 371 | Current Trends in Biotherapeutic Higher Order Structure Characterization by Irreversible Covalent Footprinting Mass Spectrometry. <i>Protein and Peptide Letters</i> , 2019, 26, 35-43.                                                                                                           | 0.4 | 5         |
| 372 | Bispecific Antibody (bsAb) Construct Formats and their Application in Cancer Therapy. <i>Protein and Peptide Letters</i> , 2019, 26, 479-493.                                                                                                                                                     | 0.4 | 8         |

| #   | ARTICLE                                                                                                                                                                                    | IF  | CITATIONS |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 373 | Characterization of Pharmaceutical IgG and Biosimilars Using Miniaturized Platforms and LC-MS/MS. <i>Current Pharmaceutical Biotechnology</i> , 2016, 17, 788-801.                         | 0.9 | 31        |
| 374 | Understanding the Monoclonal Antibody Involvement in Targeting the Activation of Tumor Suppressor Genes. <i>Current Topics in Medicinal Chemistry</i> , 2020, 20, 1810-1823.               | 1.0 | 4         |
| 375 | Recombinant Immunotoxin 4D5scFv-PE40 for Targeted Therapy of HER2-Positive Tumors. <i>Acta Naturae</i> , 2015, 7, 93-96.                                                                   | 1.7 | 6         |
| 376 | Combined Anti-Cancer Strategies Based on Anti-Checkpoint Inhibitor Antibodies. <i>Antibodies</i> , 2020, 9, 17.                                                                            | 1.2 | 14        |
| 377 | Immunogenicity of Rituximab, Trastuzumab, and Bevacizumab Monoclonal Antibodies in Patients with Malignant Diseases. <i>International Journal of Cancer Management</i> , 2018, In Press, . | 0.2 | 3         |
| 380 | Engineered antibody fusion proteins for targeted disease therapy. <i>Trends in Pharmacological Sciences</i> , 2021, 42, 1064-1081.                                                         | 4.0 | 23        |
| 381 | Expression and purification of monoclonal antibodies: what we can do in a basic research laboratory. <i>Materials and Methods</i> , 0, 6, .                                                | 0.0 | 0         |
| 382 | Antibodies at the Center of Immunotherapy: Commentary on "Moving a Carbohydrate Mimetic Peptide into the Clinic". <i>Journal of Vaccines &amp; Vaccination</i> , 2016, 07, .               | 0.3 | 0         |
| 384 | Your patient has chronic leukemia: Now what?. <i>Cleveland Clinic Journal of Medicine</i> , 2016, 83, 575-581.                                                                             | 0.6 | 0         |
| 385 | The Future in Ovarian Cancer: Advances in Immunotherapies. , 2017, , 143-168.                                                                                                              |     | 0         |
| 386 | Monoclonal Antibodies in Pediatric Acute Lymphoblastic Leukemia. , 2017, , 201-237.                                                                                                        |     | 0         |
| 389 | Cancer Immunotherapy. , 2020, , 321-355.                                                                                                                                                   |     | 0         |
| 390 | Nanomedicines in Cancer Therapy. <i>Engineering Materials</i> , 2020, , 321-356.                                                                                                           | 0.3 | 1         |
| 391 | Macromolecules and Antibody-Based Drugs. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1248, 485-530.                                                                       | 0.8 | 3         |
| 392 | Single B cell technologies for monoclonal antibody discovery. <i>Trends in Immunology</i> , 2021, 42, 1143-1158.                                                                           | 2.9 | 63        |
| 394 | Recombinant Immunotoxin 4D5scFv-PE40 for Targeted Therapy of HER2-Positive Tumors. <i>Acta Naturae</i> , 2015, 7, 93-6.                                                                    | 1.7 | 2         |
| 396 | Lessons learned from rindopepimut treatment in patients with EGFRvIII-expressing glioblastoma. <i>Translational Cancer Research</i> , 2018, 7, S510-S513.                                  | 0.4 | 6         |
| 397 | Overexpression of B7-H3 as an opportunity for targeted therapy in head and neck cancers. <i>American Journal of Translational Research (discontinued)</i> , 2019, 11, 5183-5196.           | 0.0 | 6         |

| #   | ARTICLE                                                                                                                                                                                                | IF   | CITATIONS |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 398 | Immunotherapy in anaplastic thyroid cancer. American Journal of Translational Research (discontinued), 2020, 12, 974-988.                                                                              | 0.0  | 10        |
| 399 | Anticancer therapeutics: a brief account on wide refinements. American Journal of Cancer Research, 2020, 10, 3599-3621.                                                                                | 1.4  | 1         |
| 400 | Improving antibody drug development using bionanotechnology. Current Opinion in Biotechnology, 2022, 74, 137-145.                                                                                      | 3.3  | 5         |
| 401 | Labeling of Anti-SAS1B with Zirconium-89 as a Novel Immune-PET Probe for Uterine Cancer Imaging. Journal of Biosciences and Medicines, 2021, 09, 30-41.                                                | 0.1  | 0         |
| 402 | An improved iliac lymph node method for production of monoclonal antibodies. Development Growth and Differentiation, 2022, 64, 38-47.                                                                  | 0.6  | 5         |
| 403 | Volume and trends of adalimumab and pembrolizumab reimbursed market: the Bulgarian perspective. Biotechnology and Biotechnological Equipment, 2021, 35, 1778-1791.                                     | 0.5  | 0         |
| 404 | Quantifying protein abundance on single cells using split-pool sequencing on DNA-barcoded antibodies for diagnostic applications. Scientific Reports, 2022, 12, 884.                                   | 1.6  | 3         |
| 405 | Partial Magneto-Endosomalysis for Cytosolic Delivery of Antibodies. Bioconjugate Chemistry, 2022, 33, 363-368.                                                                                         | 1.8  | 3         |
| 406 | Retrospective analysis of the preparation and application of immunotherapy in cancer treatment (Review). International Journal of Oncology, 2022, 60, .                                                | 1.4  | 7         |
| 407 | Antibody-incorporated Nanomedicines for Cancer Therapy. Advanced Materials, 2022, 34, e2109210.                                                                                                        | 11.1 | 32        |
| 408 | Investigating a Boronate-Affinity-Guided Acylation Reaction for Labelling Native Antibodies. Chemistry - A European Journal, 2022, 28, .                                                               | 1.7  | 4         |
| 409 | Emerging new therapeutic antibody derivatives for cancer treatment. Signal Transduction and Targeted Therapy, 2022, 7, 39.                                                                             | 7.1  | 158       |
| 410 | Combination therapy for pancreatic cancer: anti-PD-(L)1-based strategy. Journal of Experimental and Clinical Cancer Research, 2022, 41, 56.                                                            | 3.5  | 20        |
| 411 | Targeting delivery of synergistic dual drugs with elastic PEG-modified multi-functional nanoparticles for hepatocellular carcinoma therapy. International Journal of Pharmaceutics, 2022, 616, 121567. | 2.6  | 5         |
| 412 | Monoclonal antibodies against rabies: current uses in prophylaxis and in therapy. Current Opinion in Virology, 2022, 53, 101204.                                                                       | 2.6  | 21        |
| 413 | Angiogenic biomolecules specific nanobodies application in cancer imaging and therapy; review and updates. International Immunopharmacology, 2022, 105, 108585.                                        | 1.7  | 2         |
| 414 | Blood glucose related adverse drug reaction of antitumor monoclonal antibodies: a retrospective analysis using Vigibase. Brazilian Journal of Pharmaceutical Sciences, 0, 58, .                        | 1.2  | 3         |
| 415 | Immune- and Non-Immune-Mediated Adverse Effects of Monoclonal Antibody Therapy: A Survey of 110 Approved Antibodies. Antibodies, 2022, 11, 17.                                                         | 1.2  | 16        |



| #   | ARTICLE                                                                                                                                                                                                  | IF  | CITATIONS |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 416 | In silico analyses of the human sperm-specific antigen 2 and its role in oral squamous cell carcinoma. , 0, , .                                                                                          |     | 1         |
| 417 | Research Progress on Quantification Methods of Drug Concentration of Monoclonal Antibodies. Current Pharmaceutical Analysis, 2022, 18, .                                                                 | 0.3 | 0         |
| 418 | The Use of Antibody-Antibiotic Conjugates to Fight Bacterial Infections. Frontiers in Microbiology, 2022, 13, 835677.                                                                                    | 1.5 | 25        |
| 419 | De novo discovery of peptide-based affinity ligands for the fab fragment of human immunoglobulin G. Journal of Chromatography A, 2022, 1669, 462941.                                                     | 1.8 | 13        |
| 420 | Stromal oncostatin M cytokine promotes breast cancer progression by reprogramming the tumor microenvironment. Journal of Clinical Investigation, 2022, 132, .                                            | 3.9 | 21        |
| 421 | Mechanistic insights expatiating the biological role and regulatory implications of estrogen and HER2 in breast cancer metastasis. Biochimica Et Biophysica Acta - General Subjects, 2022, 1866, 130113. | 1.1 | 6         |
| 422 | Nanotechnology-based multifunctional vaccines for cancer immunotherapy. Chemical Engineering Journal, 2022, 437, 135505.                                                                                 | 6.6 | 13        |
| 423 | Multiple Tolerization Subtractive Immunization (MTSI) Protocol: Effects on Mice and Monoclonal Antibody Specificity. Frontiers in Immunology, 2021, 12, 760817.                                          | 2.2 | 2         |
| 424 | Bispecific antibody-activated T cells enhance NK cell-mediated antibody-dependent cellular cytotoxicity. Journal of Hematology and Oncology, 2021, 14, 204.                                              | 6.9 | 13        |
| 425 | Smart Lipid-Based Nanosystems for Therapeutic Immune Induction against Cancers: Perspectives and Outlooks. Pharmaceutics, 2022, 14, 26.                                                                  | 2.0 | 15        |
| 426 | Efficacy of Different Immunological Approaches Targeting CD22 for the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia: A Research Protocol. , 2022, 6, 1-8.                             |     | 0         |
| 437 | Monoclonal antibody-based therapies for Waldenström's macroglobulinemia. Leukemia Research Reports, 2022, 17, 100324.                                                                                    | 0.2 | 1         |
| 438 | Recent Advancements in Antifibrotic Therapies for Regression of Liver Fibrosis. Cells, 2022, 11, 1500.                                                                                                   | 1.8 | 14        |
| 439 | HSP90 N-terminus inhibitors target oncoprotein MORC2 for autophagic degradation and suppress MORC2-driven breast cancer progression. Clinical and Translational Medicine, 2022, 12, e825.                | 1.7 | 8         |
| 440 | Approaches and materials for endocytosis-independent intracellular delivery of proteins. Biomaterials, 2022, 286, 121567.                                                                                | 5.7 | 19        |
| 441 | Research Progress of Antibody-Drug Conjugate Therapy for Advanced Gastric Cancer. Frontiers in Oncology, 0, 12, .                                                                                        | 1.3 | 4         |
| 442 | Recent progress in antibody-based therapeutics for triple-negative breast cancer. Expert Opinion on Drug Delivery, 2022, 19, 815-832.                                                                    | 2.4 | 4         |
| 443 | Expression of mammalian proteins for diagnostics and therapeutics: a review. Molecular Biology Reports, 2022, 49, 10593-10608.                                                                           | 1.0 | 5         |



| #   | ARTICLE                                                                                                                                                                                                                            | IF  | CITATIONS |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 445 | Targeting stem cells in myelodysplastic syndromes and acute myeloid leukemia. <i>Journal of Internal Medicine</i> , 2022, 292, 262-277.                                                                                            | 2.7 | 7         |
| 446 | Enzymatic Reaction Automation in Nanodroplet Microfluidic for the Quality Control of Monoclonal Antibodies. <i>Biochip Journal</i> , 2022, 16, 317-325.                                                                            | 2.5 | 4         |
| 447 | Detergent micelle conjugates containing amino acid monomers allow purification of human IgG near neutral pH. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2022, 1206, 123358. | 1.2 | 2         |
| 448 | Dostarlimab as a Miracle Drug: Rising Hope against Cancer Treatment. <i>Biosensors</i> , 2022, 12, 617.                                                                                                                            | 2.3 | 30        |
| 449 | In vitro/in vivo degradation analysis of trastuzumab by combining specific capture on HER2 mimotope peptide modified material and LC-QTOF-MS. <i>Analytica Chimica Acta</i> , 2022, 1225, 340199.                                  | 2.6 | 4         |
| 450 | Tailoring radiotherapies and nanotechnology for targeted treatment of solid tumors. <i>Coordination Chemistry Reviews</i> , 2022, 472, 214757.                                                                                     | 9.5 | 14        |
| 452 | Nanotechnology Advances in the Detection and Treatment of Cancer: An Overview. <i>Nanotheranostics</i> , 2022, 6, 400-423.                                                                                                         | 2.7 | 43        |
| 453 | Antibody-drug conjugates for targeted delivery. , 2022, , 377-419.                                                                                                                                                                 |     | 0         |
| 454 | Induced CD45 Proximity Potentiates Natural Killer Cell Receptor Antagonism. <i>ACS Synthetic Biology</i> , 2022, 11, 3426-3439.                                                                                                    | 1.9 | 2         |
| 455 | Single-cell transcriptome sequencing reveals potential novel combination of biomarkers for antibody-based cancer therapeutics in hepatocellular carcinoma. <i>Frontiers in Genetics</i> , 0, 13, .                                 | 1.1 | 0         |
| 457 | Photon Upconversion in Small Molecules. <i>Molecules</i> , 2022, 27, 5874.                                                                                                                                                         | 1.7 | 2         |
| 458 | Antibody-Drug Conjugates for Melanoma and Other Skin Malignancies. <i>Current Treatment Options in Oncology</i> , 2022, 23, 1428-1442.                                                                                             | 1.3 | 1         |
| 460 | Investigation of the therapeutic potential of recombinant bispecific bivalent anti-PD-L1/VEGF nanobody in inhibition of angiogenesis. <i>Immunopharmacology and Immunotoxicology</i> , 2023, 45, 197-202.                          | 1.1 | 5         |
| 461 | Harnessing Immunologic Tools to Treat Gynecologic Disorders. <i>Current Women's Health Reviews</i> , 2023, 19, .                                                                                                                   | 0.1 | 0         |
| 462 | Tumor microenvironment and immunotherapy of oral cancer. <i>European Journal of Medical Research</i> , 2022, 27, .                                                                                                                 | 0.9 | 24        |
| 463 | Holdase/Foldase Mimetic Nanochaperone Improves Antibody-Based Cancer Immunotherapy. <i>Small Methods</i> , 2023, 7, .                                                                                                              | 4.6 | 6         |
| 464 | Targeted delivery of harmine to xenografted human pancreatic islets promotes robust cell proliferation. <i>Scientific Reports</i> , 2022, 12, .                                                                                    | 1.6 | 1         |
| 465 | Clearance of therapeutic antibody glycoforms after subcutaneous and intravenous injection in a porcine model. <i>MAbs</i> , 2022, 14, .                                                                                            | 2.6 | 2         |

| #   | ARTICLE                                                                                                                                                                                        | IF  | CITATIONS |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 466 | Antitumor Activity of an Anti-EGFR/HER2 Bispecific Antibody in a Mouse Xenograft Model of Canine Osteosarcoma. <i>Pharmaceutics</i> , 2022, 14, 2494.                                          | 2.0 | 0         |
| 468 | Size-advantage of monovalent nanobodies against the macrophage mannose receptor for deep tumor penetration and tumor-associated macrophage targeting. <i>Theranostics</i> , 2023, 13, 355-373. | 4.6 | 7         |
| 469 | Ultrasound-targeted microbubble destruction remodels tumour microenvironment to improve immunotherapeutic effect. <i>British Journal of Cancer</i> , 2023, 128, 715-725.                       | 2.9 | 14        |
| 470 | Enhanced antibody-defucosylation capability of $\alpha$ -L-fucosidase by proximity-based protein fusion. <i>Biochemical and Biophysical Research Communications</i> , 2023, 645, 40-46.        | 1.0 | 2         |
| 471 | Targeted Drug Delivery Using a Plug-to-Direct Antibody-Nanogel Conjugate. <i>Biomacromolecules</i> , 2023, 24, 849-857.                                                                        | 2.6 | 6         |
| 472 | Discovery of the Potent and Highly Selective PARP7 Inhibitor as a Novel Immunotherapeutic Agent for Tumors. <i>Journal of Medicinal Chemistry</i> , 2023, 66, 473-490.                         | 2.9 | 10        |
| 474 | Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) in Cancer. , 2023, , 1-21.                                                                                                                |     | 0         |
| 475 | Leading Edge: Intratumor Delivery of Monoclonal Antibodies for the Treatment of Solid Tumors. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2676.                             | 1.8 | 6         |
| 476 | Emerging Trends in Monoclonal Antibody Therapies Targeting Cancer. , 2023, , 1-48.                                                                                                             |     | 0         |
| 477 | Antibodies as Therapeutic Agents. , 2023, , 131-161.                                                                                                                                           |     | 0         |
| 478 | Tuning Nanobodies™ Bioactivity: Coupling to Ultrasmall Gold Nanoparticles Allows the Intracellular Interference with Survivin. <i>Small</i> , 2023, 19, .                                      | 5.2 | 2         |
| 479 | Progress of Cancer Nano Medicine, Clinical Hurdles, and Opportunities. , 2022, , 49-69.                                                                                                        |     | 0         |
| 480 | Monoclonal antibodies in breast cancer: A critical appraisal. <i>Critical Reviews in Oncology/Hematology</i> , 2023, 183, 103915.                                                              | 2.0 | 5         |
| 481 | Generation of a single-cell B cell atlas of antibody repertoires and transcriptomes to identify signatures associated with antigen specificity. <i>IScience</i> , 2023, 26, 106055.            | 1.9 | 3         |
| 482 | ROCKETS – a novel one-for-all toolbox for light sheet microscopy in drug discovery. <i>Frontiers in Immunology</i> , 0, 14, .                                                                  | 2.2 | 1         |
| 484 | Treatment options for patients with human epidermal growth factor 2-positive breast cancer brain metastases: A systematic review and meta-analysis. <i>Frontiers in Oncology</i> , 0, 13, .    | 1.3 | 1         |
| 485 | Multiplex Identification of Post-Translational Modifications at Point-of-Care by Deep Learning-Assisted Hydrogel Sensors. <i>Angewandte Chemie</i> , 2023, 135, .                              | 1.6 | 0         |
| 486 | Bispecific T-Cell Engagers Therapies in Solid Tumors: Focusing on Prostate Cancer. <i>Cancers</i> , 2023, 15, 1412.                                                                            | 1.7 | 5         |

| #   | ARTICLE                                                                                                                                                                                  | IF   | CITATIONS |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 487 | Operating Parameters Optimization for the Production of Liposomes Loaded with Antibodies Using a Supercritical Fluid-Assisted Process. <i>Processes</i> , 2023, 11, 663.                 | 1.3  | 1         |
| 488 | Multiplex Identification of Post-Translational Modifications at Point-of-Care by Deep Learning-Assisted Hydrogel Sensors. <i>Angewandte Chemie - International Edition</i> , 2023, 62, . | 7.2  | 3         |
| 489 | Introduction to Protein Therapeutics. , 2023, , 1-22.                                                                                                                                    |      | 0         |
| 490 | Rabbit derived VL single-domains as promising scaffolds to generate antibody-drug conjugates. <i>Scientific Reports</i> , 2023, 13, .                                                    | 1.6  | 1         |
| 491 | Zebrafish in Drug Discovery: Safety Assessment. , 2022, , 1-21.                                                                                                                          |      | 0         |
| 492 | Preclinical development of a first-in-class vaccine encoding HER2, Brachyury and CD40L for antibody enhanced tumor eradication. <i>Scientific Reports</i> , 2023, 13, .                  | 1.6  | 1         |
| 493 | New Developments and Challenges in Antibody-Based Therapies for the Respiratory Syncytial Virus. <i>Infection and Drug Resistance</i> , 0, Volume 16, 2061-2074.                         | 1.1  | 2         |
| 494 | Immunotherapeutic and their immunological aspects: Current treatment strategies and agents. <i>National Journal of Maxillofacial Surgery</i> , 2022, 13, 322.                            | 0.1  | 1         |
| 495 | Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy. <i>Nature Communications</i> , 2023, 14, .                      | 5.8  | 15        |
| 496 | Vacuolated coacervate mediates the bimodal release kinetics of diverse macromolecular drugs in vivo. <i>Materials Today</i> , 2023, , .                                                  | 8.3  | 0         |
| 506 | The Dawn of a New Era: Targeting the "Undruggables" with Antibody-Based Therapeutics. <i>Chemical Reviews</i> , 2023, 123, 7782-7853.                                                    | 23.0 | 13        |
| 515 | Investigating Conventional and Novel Methods for Treatment of Cancer. , 2023, , .                                                                                                        |      | 0         |
| 517 | Single B-cell sequencing in monoclonal antibody discovery. , 2024, , 73-95.                                                                                                              |      | 0         |
| 525 | Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities. , 2023, , 311-386.                                                                                        |      | 0         |
| 526 | Immunotherapy for ALL. , 2023, , 341-352.                                                                                                                                                |      | 0         |
| 543 | Antibody-drug conjugates in cancer therapy: innovations, challenges, and future directions. <i>Archives of Pharmacal Research</i> , 2024, 47, 40-65.                                     | 2.7  | 1         |